Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 1.00 |
| ▸ | CNR1 | P21554 | 4/20 | 1.00 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.58 |
| ▸ | GBA1 | P04062 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | PARG | Q86W56 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.45 |
| ▸ | IDH2 | P48735 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13456174 | 0.82 | CNR2 (0.74) | CNR2CNR1MEN1KMT2A | |
| SCHEMBL3038875 | 0.81 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL6799277 | 0.81 | GBA1 (0.69) | CNR2CNR1GBA1HTR1ADRD2 | |
| SCHEMBL14606690 | 0.74 | GBA1 (0.59) | CNR2CNR1GBA1HTR1ADRD2 | |
| SCHEMBL1594065 | 0.74 | GBA1 (0.59) | CNR2CNR1GBA1HTR1ADRD2 | |
| SCHEMBL3043510 | 0.74 | CNR1 (0.70) | CNR2CNR1SOS1MEN1KMT2A | |
| SCHEMBL18025447 | 0.74 | SOS1 (1.00) | CNR2CNR1SOS1 | |
| SCHEMBL3035205 | 0.73 | CNR2 (1.00) | CNR2CNR1GBA1NPC1MEN1 | |
| SCHEMBL3025163 | 0.73 | CNR2 (0.57) | CNR2CNR1GBA1NPC1PARG | |
| SCHEMBL7263560 | 0.72 | GBA1 (0.65) | CNR2CNR1GBA1PARGMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056528-A1 | SULFONAMIDE DERIVATIVES WITH THERAPEUTIC INDICATIONS | PHARMOS CORPORATION | 2010-03-04 | — | — | US | claimed |
| EP-2139852-A1 | SULFONAMIDE DERIVATIVES WITH THERAPEUTIC INDICATIONS | Pharmos Corporation (US) | 2010-01-06 | — | — | EP | claimed |
| WO-2008075353-A1 | SULFONAMIDE DERIVATIVES WITH THERAPEUTIC INDICATIONS | PHARMOS CORPORATION (US) | 2008-06-26 | — | — | WO | claimed |
| US-9422235-B2 | Sulfonamide derivatives with therapeutic indications | PHARMOS CORPORATION (US) | 2016-08-23 | — | — | US | disclosed |
| US-9422235-B2 | Sulfonamide derivatives with therapeutic indications | PHARMOS CORPORATION (US) | 2016-08-23 | — | — | US | disclosed |
| US-20100056528-A1 | SULFONAMIDE DERIVATIVES WITH THERAPEUTIC INDICATIONS | PHARMOS CORPORATION | 2010-03-04 | — | — | US | disclosed |
| US-20100056528-A1 | SULFONAMIDE DERIVATIVES WITH THERAPEUTIC INDICATIONS | PHARMOS CORPORATION | 2010-03-04 | — | — | US | disclosed |
| EP-2139852-A1 | SULFONAMIDE DERIVATIVES WITH THERAPEUTIC INDICATIONS | Pharmos Corporation (US) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008075353-A1 | SULFONAMIDE DERIVATIVES WITH THERAPEUTIC INDICATIONS | PHARMOS CORPORATION (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056528-A1 | SULFONAMIDE DERIVATIVES WITH THERAPEUTIC INDICATIONS | SULT2A1, STS, SULT1A1 | CNR2 41/4885CNR1 207/4885SOS1 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.